HLA-DRB1 antibody (N-Term)

Catalog No. ABIN2795073

The Rabbit Polyclonal anti-HLA-DRB1 antibody (ABIN2795073) specifically detects HLA-DRB1 in WB, FACS and IHC. The antibody is reactive with Human samples.

Quick Overview for HLA-DRB1 antibody (N-Term) (ABIN2795073)

Target: HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HLA-DRB1 antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (IHC)

Product Details anti-HLA-DRB1 Antibody

Binding Specificity: AA 30-58, N-Term

Purpose: Rabbit Anti-Human HLA-DRB1 (N-term) Antibody

Immunogen: This HLA-D_1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 30-58 amino acids from the N-terminal region of human HLA-D_1.

Isotype: Ig Fraction

Application Details

Application Notes: Western Blot, Immunohistochemistry, Flow Cytometry
Recommended Dilutions
WB: 1:1000, IHC: 1:10-50, FC: 1:10-50Western blot analysis of HLA-DRB1 Antibody (N-term) FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.360 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: 2-8°C (short-term), -20°C (long-term)

Target Details for HLA-DRB1

Target: HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))

Alternative Name: HLA-DRB1

Background:

Target Description: HLA-DRB1 belongs to the HLA class II beta chain paralogs. The class II molecule is a heterodimer consisting of an alpha (DRA) and a beta chain (DRB), both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The beta chain is approximately 26-28 kDa. It is encoded by 6 exons.

Gene Symbol: HLA-DRB1

Molecular Weight: 29914 Da

UniProt: P04229

Pathways: TCR Signaling, Positive Regulation of Peptide Hormone Secretion, Production of Molecular Mediator of Immune Response, CXCR4-mediated Signaling Events, Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response